Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bristol-Myers Squibb Co. (BMY) PT Raised to $74 at BMO Capital
February 7, 2022 7:21 AM ESTBMO Capital analyst Evan David Seigerman raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $74.00 (from $72.00) while maintaining an Outperform rating.
The analyst commented, "Concerns around Revlimids erosion still overshadow the growth from the new product portfolio, but the... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
February 4, 2022 6:59 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.83, $0.01 better than the analyst estimate of $1.82. Revenue for the quarter came in at $12 billion versus the consensus estimate of $12.12 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 EPS of $7.65-$7.95.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
... More